Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 21Isotretinoin 14Etoposide 13Topotecan 12Irinotecan 12dinutuximab 10Temozolomide 10Magnetic Resonance Spectroscopy 10Doxorubicin 10Melphalan 9sargramostim 8Vincristine 8Filgrastim 7Cisplatin 7Specimen Handling 6Granulocyte-Macrophage Colony-Stimulating Factor 6Granulocyte Colony-Stimulating Factor 6Carboplatin 63-Iodobenzylguanidine 6X-Rays 5Phantoms, Imaging 5Busulfan 5Biopsy 5fludarabine 4etoposide phosphate 4aldesleukin 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Nuclear Medicine Department, Hospital 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroblastoma × robatumumab × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡